AMAZON.COM, INC. et al. v. Nokia Technologies Oy

IPR2024-00848

Amazon seeks director review of the Board’s decision to institute an IPR against Nokia’s ‘808 patent covering a redefined skip coding mode in video encoders. Nokia argues the Board misapplied obviousness standards and ignored the patent’s explicit lexicography.

Jurisdiction
US PTAB
Case Number
IPR2024-00848
Decision Date
5 October 2024
Filing Date
5 October 2024

Detailed Summary

In a Request for Director Review, Amazon challenges the PTAB’s institution of an Inter Partes Review of Nokia Technologies Oy’s U.S. Patent No. 7,532,808, which claims a novel “skip coding mode” for video encoders and decoders. The petition raises two obviousness grounds: (1) a combination of mutually exclusive coding options disclosed in WO 01/11891 A1 (Karczewicz) lacking any motivation or reasonable expectation of success, and (2) a misinterpretation of the inventor’s lexicography when comparing the claims to U.S. Pat. Pub. 2003/0123738 (Frojdh) and related standards. Nokia contends the Board’s findings constitute an abuse of discretion and should be vacated, preserving the patent’s enforceability.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in AMAZON.COM, INC. et al. vs Nokia Technologies Oy is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patentIPR2024-00463

Ilooda Co., Ltd. et al.vsSerendia, LLC

The PTAB institution decision found a reasonable likelihood of unpatentability for several claims in the dermatological treatment patent, primarily based on anticipation by reference Mehta. The Board rejected arguments for discretionary denial and proceeded with the IPR.

patentIPR2025-01374

Terumo BCT, Inc.vsHaemonetics Corporation

Terumo BCT argues that the IPR on Haemonetics’ blood‑a­pheresis patent should remain instituted, emphasizing that the disputed “controller” term is undisputed and that prior‑art devices disclose it.

patentPGR2025-00003

Merck Sharp & Dohme LLCvsHalozyme, Inc. et al.

Merck files a PGR petition challenging Halozyme’s protein‑based contraceptive patent, arguing the claims lack written description and enablement. The reply emphasizes that the specification does not support the broad genus of modified PH20 polypeptides claimed.

patentIPR2025-00746

Meta Platforms, Inc.vsMullen Industries LLC

Meta Platforms has filed an IPR petition seeking to invalidate three claims of Mullen Industries’ location‑based gaming patent, arguing they are obvious over the earlier Levine application. The petition cites dismissal of the patent in a related district‑court case and argues no discretionary denial factors apply.

patentIPR2025-00915

Intel Corporation et al.vsAdvanced Cluster Systems, Inc.

Intel and AMD have filed an IPR petition challenging all 30 claims of ACS’s ’621 patent covering parallel MATLAB execution on computer clusters, asserting obviousness over earlier Cornell publications and IBM documentation.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call